Cancer Home > Precautions and Warnings With Triptorelin
Some warnings and precautions to be aware of prior to receiving this medication include the following:
- Triptorelin will cause an initial rise in testosterone levels, which may lead to more symptoms when you first start treatment, such as bone pain and difficulty urinating. Contact your healthcare provider if these symptoms do not improve after a few weeks of treatment, or if they are severe.
- If your cancer has spread to your spine or urinary tract, you may be at risk for urinary tract blockage or pressure in the spine at the start of treatment, when your testosterone levels are high. These problems are potentially serious and can lead to paralysis and even death. Your healthcare provider will monitor you more closely during the first few weeks of treatment.
- Your healthcare provider may monitor your response to triptorelin by taking testosterone blood levels and prostate-specific antigen (PSA) levels. Other blood tests may be needed to monitor for potential side effects. Therefore, make sure to keep all your medical appointments with your healthcare provider.
- People with kidney or liver disease may have higher blood levels of triptorelin. This could increase the risk for side effects.
- In rare cases, this medication may cause a condition known as pituitary apoplexy, which occurs when tissue of the pituitary gland becomes damaged and dies. This can lead to pituitary gland failure. Seek immediate medical attention if you develop signs of pituitary apoplexy, such as:
- A sudden, severe headache
- An inability to move the eye
- Changes in vision
- Low blood pressure
- Medications like triptorelin have been reported to increase blood sugar levels, which could lead to diabetes, or worsen glucose control in people who have diabetes. Your healthcare provider may periodically monitor your blood sugar levels during treatment to test for diabetes, or have you check your blood sugar levels more often if you already have the condition.
- Gonadotropin-releasing hormone (GnRH) agonists, such as triptorelin, have been reported to cause stroke, heart attack, and sudden cardiac death. Although the risk appears to be low, your healthcare provider will assess your overall health before starting treatment to determine your individual risk for these serious problems. During treatment, your healthcare provider will monitor you for heart disease, and may treat other cardiovascular risk factors, such as high blood pressure and high cholesterol.
- Triptorelin may react with a few other medications (see Drug Interactions With Triptorelin for more information).
- It is unknown if this medicine passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to beginning treatment (see Trelstar and Breastfeeding).
- This product is considered a pregnancy Category X medication. This means it may harm an unborn child and should not be used in women who are pregnant or may become pregnant (see Trelstar and Pregnancy).